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Abstract
Understanding the mechanisms involved in long-term persistence of humoral immunity after natural infection or
vaccination is challenging and crucial for further research in immunology, vaccine development as well as health policy.
Long-lived plasma cells, which have recently been shown to reside in survival niches in the bone marrow, are instrumental
in the process of immunity induction and persistence. We developed a mathematical model, assuming two antibody-
secreting cell subpopulations (short- and long-lived plasma cells), to analyze the antibody kinetics after HAV-vaccination
using data from two long-term follow-up studies. Model parameters were estimated through a hierarchical nonlinear mixed-
effects model analysis. Long-term individual predictions were derived from the individual empirical parameters and were
used to estimate the mean time to immunity waning. We show that three life spans are essential to explain the observed
antibody kinetics: that of the antibodies (around one month), the short-lived plasma cells (several months) and the long-
lived plasma cells (decades). Although our model is a simplified representation of the actual mechanisms that govern
individual immune responses, the level of agreement between long-term individual predictions and observed kinetics is
reassuringly close. The quantitative assessment of the time scales over which plasma cells and antibodies live and interact
provides a basis for further quantitative research on immunology, with direct consequences for understanding the
epidemiology of infectious diseases, and for timing serum sampling in clinical trials of vaccines.
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Introduction
The human adaptive immune response relies on a complex
combination of cellular and humoral immunity, mediated by T-
and B-lymphocytes. Although vaccination aims to activate both
cellular and humoral immunity, vaccine induced immunity is
typically evaluated by means of the antibody titer, secreted by B-
lymphocytes [1]. After encountering antigens, B-cells are stimu-
lated to proliferate and/or differentiate into memory B-cells and
plasma cells (PC). Memory B-cells permit a faster and more
effective immune response upon further exposures to the antigens,
whereas PC are the main antibody-secreting cells (ASC). Different
antibody isotopes are present in human sera (IgM, IgA and IgG).
They each have relatively limited half-lives, with a maximum of
17.5–26.0 days for Immunoglobulin G (IgG), which represent
about 75% of the antibody isotopes in humans [2,3,4].
Nonetheless, exposure to common viral and vaccine antigens has
been shown to induce a long-term humoral immune response,
which illustrates that improving our understanding of the
mechanisms involved in the production and persistence of
antibodies remains a (relatively rarely explored) topic of funda-
mental scientific interest [5].
Recently, Amanna and Slifka reviewed six plausible models
describing the evolution of the humoral immune response over
time [2]. Four of these models were based on a memory B-cell
dependent process, assuming antibody production either due to
chronic or repeated infections, persisting antigen immune
complexes on the surface of follicular dendritic cells, or cross-
reactive antigen stimulation [6,7,8,9]. According to the authors,
none of these models is suitable to reproduce the evolution of
antibody levels with time after exposure to viral or vaccine
antigens. In contrast with the previous approaches, Amanna and
Slifka [2] proposed two theoretical models considering plasma cells
as an independent B-cell subpopulation that is long-lived even in
the absence of replenishment by memory B-cells [5,10]: the ‘plasma
cell niche competition model’ and the ‘plasma cell imprinted lifespan model’
[2]. There is strong evidence that plasma cells can be long-lived
when located in survival niches, especially in bone marrow and to
a lesser extent the spleen. These antibody-secreting cells could be
pivotal for the maintenance of humoral immunity [11,12,13,14].
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the assumption that there is competition between resident and new
migratory plasma cells for a finite number of survival niches. New
migratory plasma cells are unable to survive for long periods
outside of these niches. Since plasma cells accumulate in these
niches due to new infections and reinfections over time, the
average age of plasma cells occupying the niches increases.
Consequently, the duration of the humoral response they induce
should decay more rapidly with time. The latter effect remains to
be demonstrated [5]. The last model proposed by Amanna and
Slifka assumed an ‘‘imprinted’’ lifespan for antigen-specific plasma
cells [2]. This model explicitly assumed no further division of
plasma cells. In the absence of replenishment of memory B-cells
(due to reinfection or vaccine boosting), this implies that serum
antibody titers would be strongly related to the lifespan of antigen-
specific plasma cell populations. Hence, the antibody kinetics can
be assumed to evolve over three time-scales: the antibody lifespan,
with an half-life ranging between 17.5 and 26 days, the short-lived
plasma cell and long-lived plasma cell lifespans. However, as noted
by the authors, the imprinted lifespan model does not differentiate
between short lived-plasma cells and memory B-cell dependent
mechanisms, such as the role of persisting antigen stimulation in
the early antibody kinetics, but provides insights on the long-term
persistence of antibodies after infection or vaccination and the
interplay between antibody titers and plasma cell kinetics.
Although based on evidenced immunological concepts, to our
knowledge, Amanna and Slifka’s models were not used to analyze
data and remained purely theoretical.
Several mathematical models have been developed to study the
long-term persistence of vaccine-induced antibodies from serolog-
ical follow-up surveys, using either the general mean titer (GMT)
or individual antibody titers as an outcome measure. Most of these
studies estimated the decay rate of antibodies assuming a simple
exponential decay or including rapid and slow components for
decay depending on the time after vaccination. Using these
frameworks, long-term persistence (over 25 years) of hepatitis A
(HAV) vaccine-induced immunity was demonstrated
[15,16,17,18,19]. Fraser et al. [20] proposed a model accounting
explicitly for B-cell population (antibody secreting cells) kinetics
and extended their model by differentiating an ‘‘activated’’ and a
memory B-cell subpopulation [20,21]. In the present study, a
mathematical formulation of the ‘‘plasma-cell imprinted lifespan’’
model proposed by Amanna and Slifka [2] was implemented and
used to estimate long-term persistence of anti-HAV antibodies
from two 10-year follow-up studies in adults vaccinated with
inactivated hepatitis A vaccines.
Materials and Methods
Data
Two long-term follow-up datasets were used for parameter
estimation. Healthy HAV-seronegative adults aged between 18
and 40 years were enrolled after giving their written informed
consent [17]. The first dataset included 289 subjects vaccinated
with 2 doses of Havrix
TM 1440 with 0-6 (109 individuals) or 0–12
months (180 individuals) vaccination schedules. This inactivated
hepatitis A vaccine, manufactured by SmithKline Beecham
Biologicals and introduced in 1994, was formulated to contain
no less than 1440 ELISA units (El.U) of hepatitis A antigen (strain
HM175) per 1 ml dose, adsorbed onto 0.5 mg of aluminium salts.
Subjects received the vaccine in the right deltoid muscle. Various
vaccination schedules were shown to provide similar immune
responses [22]. Blood samples were taken in each participant
before vaccination, to ensure seronegativity, as well as between the
primary and boosting doses, and after booster administration. In
view of our aim with the present study - the evaluation of long-
term persistence of antibodies after a full vaccination schedule, the
dataset we use here is limited to time-points after boosting, i.e. at 1,
12, 18, 24, 30, 36, 42, 48, 50, 66, 78, 90, 102, 114 and 126 months
after boosting. The second dataset included 113 subjects
vaccinated with 3 doses of Havrix
TM 720 according to a 0-, 1-,
6-vaccination schedule [16,23]. This vaccine, which is the
predecessor formulation of Havrix
TM 1440, contained no less
than 720 Elisa units per 1.0-ml dose. Blood samples were taken at
1, 6, 12, 18, 30, 42, 54, 66, 78, 90, 102 and 114 months after the
booster dose (6 months). Antibody titration was performed using
an ‘‘in-house’’ ELISA inhibition assay [24]. Subjects with antibody
levels below 20 mIU/ml for the ELISA test were considered
seronegative.
Mathematical models of antibody kinetics
The ‘‘plasma-cell imprinted lifespan’’ model accounting for the
dynamics of plasma cell (P) and antibody (A) populations was
considered. The plasma cell population is divided in two
subpopulations according to their specific lifespan: short- and
long-lived plasma cells denoted by Ps and Pl, respectively.
Assuming no renewal, plasma cell populations decline over time
with different decay rates according to their longevity. However,
long-lived plasma cells can survive for long periods of time residing
in survival niches, mainly in the bone marrow, and could
consequently be considered as virtually steady [2,13,14]. Finally,
assuming that the antibody lifespan is short relatively to plasma
cell lifespan, antibody kinetics can be considered to reflect the
underlying kinetics of plasma cell populations [2]. Owing to these
different assumptions, three nested models were explored.
Complete model. The dynamics of plasma cell and antibody
populations are described by the following system of differential
equations:
dPs
dt
~{msPs
dPl
dt
~{mlPl
dA
dt
~QsPszQlPl{mAA
A(0)~A0,Ps(0)~P0
s,Pl(0)~P0
l
8
> > > > > > > > <
> > > > > > > > :
ð1Þ
Where ms,ml and mA represent the average decay rates of short-
lived plasma cells, long-lived plasma cells and antibodies,
Author Summary
Recent studies evidenced the existence of long-lived
plasma-cells which could play a major role in the long-
term persistence of antibodies after infection or vaccina-
tion. A mathematical model, accounting for two plasma-
cells populations (short and long-lived), was developed to
analyze data from two long-term follow-up studies in
patients vaccinated with hepatitis A inactivated vaccines.
Parameter estimates confirmed the importance of three
time scales to explain the decay of antibody levels: the
antibodies lifespan (around one month), the short-lived
plasma cells lifespan (several months) and the long-lived
plasma cells lifespan (decades). This study also highlighted
the need of more frequent observations during the first
year post-vaccination to estimate accurately the different
parameters governing the long-term antibody dynamics.
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short- and long-lived plasma cells, A0 is the initial antibody level,
P0
s and P0
l are the initial population sizes of short- and long-lived
plasma cells.
This system has the following analytical solution:
Ps(t)~P0
s exp({mst)
Pl(t)~P0
l exp({mlt)
A(t)~
Ws
mA{ms
e{mstz
Wl
mA{ml
e{mltzA0{
Ws
mA{ms
{
Wl
mA{ml
  
e{mAt
8
> > > <
> > > :
ð2Þ
where Ws~QsP0
s and Wl~QlP0
l
Asymptotic model. Assuming that the lifespan of long-lived
plasma cells is infinity, i.e. ml~0, the asymptotic total antibody
production rate is a constant different from zero Wl=mA ðÞ . Solution
(2) then becomes
A(t)~
Wl
mA
z
Ws
mA{ms
e{mstz A0{
Ws
mA{ms
{
Wl
mA
  
e{mAt, ð3Þ
Plasma cell driven kinetic (PCDK) model. Assuming that
the antibody lifespan is short relatively to plasma cell lifespan
ms,l=mAvv1
  
, the antibody kinetics can be considered as being
an immediate reflection of the underlying kinetics of plasma cell
populations [2]. Solution (2) amounts then to
A(t)~bse{mstzble{mlt, ð4Þ
where bs~Ws=mA and bl~Wl=mA.
Parameter estimation
A non-linear mixed effects model was used to estimate model
parameters mA,ms,ml,Ws,Wl,bs,bl ðÞ as described by Snoeck et al.
[25]. Briefly, individual parameters are assumed to be log-
normally distributed and were used to predict the antibody titer
in an individual iat a certain point in time j (Apred,ij) [25]. The
measured antibody-titers (Aobs,ij) were log10-transformed for the
analysis with an additive residual-error:
log10 Aobs,ij
  
~log10 Apred,ij
  
zeij
The eij values are assumed to be normally distributed with mean
zero and variance s2. Population parameters were estimated using
MLE by the SAEM algorithm for the hierarchical nonlinear
mixed-effects model analysis using Monolix software (http://www.
monolix.org) [26].
A nonparametric bootstrap procedure was used to determine
the 95% confidence intervals of parameter estimates permitting
the evaluation of the accuracy of parameter estimates. One
thousand bootstrap replicates were generated by resampling
individual profiles for each dataset. For each bootstrap replicate,
each model was refitted to get an estimate of the population
parameters. The 95% confidence interval was constructed from
the 2.5
th and 97.5
th percentiles for each of the population
parameters [27]. For each bootstrap replicate, long-term extrap-
olations of antibody decay were obtained, resulting in predictions
and 95% confidence intervals of the mean duration of vaccine-
induced immunity (antibody titers higher than 20mUI/ml), as well
as the mean time for the proportion of immune individuals to
decrease down to 95% and 90%.
Alternative modeling assumptions: the power-law
models
Fraser et al. [20] proposed an alternative to exponential
distributions of decay rates, assuming an heterogeneity in the
decay rate of B-cells expressed by a gamma distribution. This
hypothesis led to the formulation of the so-called ‘‘conventional
power-law’’ model previously used to model antibody persistence
[28,29,30]. In [20], this model was further improved to account
for two B-cell subpopulations leading to an ‘‘asymptotic model’’,
assuming that a proportion of the B-cell population does not
decrease, and a ‘‘full model’’, assuming a slower decay rate for a
proportion of the B-cell population. Using the notations in [20],
these three models describing the antibody kinetics are given by:
1. Conventional power-law model
f(t)~k{alog10(czt),
2. Asymptotic power-law model
f(t)~kzlog10((1{p)(czt)
{azp),
3. Full power-law model
f(t)~kzlog10((1{p)(czt)
{azp(czt)
{b),
where f(t) is the log10-transform of antibody titer at time t, kis the
peak log10-level, a and b represent the decay rates of short-lived
and long-lived plasma cells, respectively, and c is an arbitrary
constant (often set to 0). Finally, p (0vpv1) is the relative level of
antibodies produced in the long-term plateau. Using the same
methodology as previously described, parameters were estimated
for each power-law model.
Model diagnostic
AIC (Akaike Information Criterion) was used for model
selection. As population based diagnostics were not very
informative, goodness of fit was assessed based on diagnostic plots
for the individual predictions (IPRED), and individual weighted
residuals (IWRES) by calculation of the e-shrinkage [31].
Results
Parameter estimates are given in Table 1. For the complete
model, the population average antibody decay rates were close to
0.8 for both datasets (95% confidence intervals [0.63, 1.34] and
[0.65, 1.36] for the first and second datasets, respectively),
corresponding to a half-life of 26 days. Under the assumption of
the asymptotic model, the average decay rate obtained with the
first dataset (0.75 [0.49, 1.10]) was slightly lower than the one
obtained with the second dataset (0.95 [0.68, 1.48]); these values
remained consistent with the literature (half-lives of 27.7 and 21.9
days, respectively) [2]. Using the individual estimates of the decay
rate parameter provided by Monolix as the mean of their posterior
distribution [26], we performed Kruskal-Wallis tests to investigate
the difference between the kinetics at early time-points after the
boosting dose according to model assumptions (complete and
asymptotic) and vaccine formulation (Havrix
TM 1440 and
Havrix
TM 720). Although no difference was found between the
Dynamics of Plasma Cell and Antibody Populations
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the two vaccines, with a higher decay rate for the oldest vaccine
(Havrix
TM 720; p=0.004). However, this difference could also be
due to the inclusion of the 6-month time-point in the second
dataset which allows for a decomposition of the kinetics according
to the different population time-scales. Moreover, under the
asymptotic assumption (lowest AIC), the inter-individual variabil-
ity, estimated as the standard deviation of random-effects [26], was
reduced from 84% (Havrix
TM 1440) with the first dataset to 61%
for the second dataset (Havrix
TM 720). Note that when looking at
the exclusion of random effects one by one, all were significant
(5% significance level) based on a 50:50 mixture of a x2(0) and
x2(1) distribution.
Testing whether ml is significantly different from 0 was done
using a likelihood ratio test for which the asymptotic null
distribution is a 50:50 mixture of a x2(0) and x2(1) distribution
[32,33]. The estimate of ml was not found to be significantly
different from 0 with the complete model, meaning that the
lifespan of long-lived plasma cells cannot be estimated and this
subpopulation could be considered constant. Nevertheless, the
inclusion of a supplementary data-point in the early stage of the
kinetics (6 month post-boosting; Havrix
TM 720 dataset) permitted
to improve the estimation accuracy for the long-lived plasma-cells
decay rate, decreasing substantially the relative standard error
(RSE) of the estimate from 2e
4% for the first dataset to 231% for
the second (data not shown). Discarding the additional 6-month
data point from the second dataset, the asymptotic model resulted
in estimates of the antibody decay rate close to the one obtained
with the first dataset (data not shown). This result suggests that
more time points during the first year would allow estimating the
three time scales using the complete model. The third model
(PCDK) assumed that the antibody decay rate can be ignored
relative to the plasma-cell kinetics, leading to an ‘‘adiabatic’’
formulation. For both datasets, the time scales obtained for the
short- and long-lived plasma cell lifespan differ by two orders of
magnitude. For the first dataset (Havrix
TM 1440), the estimated
lifespan of short-lived plasma cells (1=ms), averaged around 7
months, which is much longer than the 1 month antibody lifespan.
The estimated lifespan of long-lived plasma cells, averaged around
60 years (i.e. roughly similar to the average human lifespan). For
the second dataset (Havrix
TM 720), the estimated lifespan of short-
lived plasma cells was close to 1 months and the estimated lifespan
of long-lived plasma cells was only 10 years. However, due to the
additional measurement at 6 months after the (final) booster dose
the adiabatic assumption is no longer valid (ignoring the antibody
lifespan compared to the plasma cell lifespan). Indeed, at the 6
months post booster point, the observed antibody kinetics are
principally driven by the antibody decay rate, implying that we
can no longer assume that its effect is negligible relative to that of
the plasma-cell kinetics. In both cases, the estimates of ms are the
result of a combination of antibody and short-lived plasma cell
decays. However, the lifespan of long-lived plasma cells,
contributing to long-term persistence of the humoral response,
was found to be 6-fold longer with the more recent and more
potent vaccine formulation (Havrix
TM 1440) than with the older
formulation (Havrix
TM 720). The conventional power-law model
assumes that the antibody level declines continuously with time
but the data suggest the existence of at least two phases of decline:
a short-term component with a high decay rate in the first 2 years
of observation, followed by a long-term component which could
be thought as a ‘‘plateau’’ phase. The results obtained for the two
datasets using the conventional power-law model are similar with
a low decay rate (a=0.63) reflecting both phases using only one
parameter (Table 2). The inclusion of an asymptotic phase in the
modified power-law model allows for a focus on the short term
dynamics. For both datasets, the decay rate estimates were
drastically increased compared with conventional power-law
approaches. The decay rate obtained with the second dataset
was slightly lower than for the first dataset, but combined with a
lower peak of the antibody titer, the immunity provided by the
Havrix
TM 720 vaccine remains weakest compared to the more
recent Havrix
TM 1440 vaccine. Finally, the introduction of the
second time scale, governing the long-term behaviour, referred as
‘‘full power-law model’’ supports the results obtained in our study:
the presence of a supplementary point (6 months post-boosting) in
the second dataset allow for a better estimation of the long-term
component. The results obtained with the first dataset are close to
the ones obtained with the asymptotic model with a decay rate
Table 1. Parameter estimates according to the modeling assumptions: complete, asymptotic or plasma-cell driven kinetics (PCDK)
model (95% confidence intervals determined using bootstrap percentile intervals).
Population parameter estimates (CI)
Havrix
TM 1440 dataset Havrix
TM 720 dataset
Parameters Complete Model Asymptotic Model PCDK Model Complete Model Asymptotic Model PCDK Model
Ws (1e
3 mIU/ml*
Month
21)
1.12 (0.81, 2.20) 1.04 (0.55, 1.71) - 1.00 (0.65, 1.37) 0.97 (0.68, 1.72) -
Wl (1e
3 mIU/ml*
Month
21)
0.54 (0.43, 0.92) 0.51 (0.33, 0.75) - 0.26 (0.20, 0.59) 0.40 (0.20, 0.65) -
bs (1e
3 mIU/ml) - - 3.38 (2.95, 3.96) - - 5.56 (3.89, 8.01)
bl (1e
3 mIU/ml) - - 0.84 (0.70, 0.97) - - 1.43 (1.15, 1.71)
ms (Month
21) 0.069 (0.062, 0.080) 0.07 (0.058, 0.074) 0.14 (0.12, 0.16) 0.014 (0.011, 0.026) 0.02 (0.013, 0.028) 0.76 (0.51, 1.04)
ml (Month
21) 1.8e
26 (5.2e-7, 7.8e-6) - 1.5e
23 (3.03e-5, 2.3e
23) 9.8e
24 (1.4e
24, 1.3e
23) - 8.1e
23 (6.1e
23, 9.8e
23)
mA (Month
21) 0.79 (0.63, 1.34) 0.75 (0.49, 1.10) - 0.82 (0.65, 1.36) 0.95(0.68, 1.48) -
A0 (1e
3 mIU/ml) 7.79 (6.38, 12.21) 7.60 (5.90, 10.66) - 8.62 (6.32, 14.6) 9.26 (6.27, 15.41) -
AIC 21626.63 21630.63 21354.10 2346.2 2346.35 2308.16
e-shrinkage (%) 16 16 13 18 17 13
doi:10.1371/journal.pcbi.1002418.t001
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estimate a decay rate of 0.37 for long-lived plasma cells resulting in
a slow but continuous decay of the antibody population.
All models showed a good consistency between individual
predictions and observations with e-shrinkage estimated between
13 and 18%. Additional data points in the early phase of the
kinetics might decrease the e-shrinkage as they provide more
information on high-level antibodies. Among the six models
considered throughout this study, the lowest AIC was obtained
with the asymptotic model assuming exponential decays for
antibodies and plasma cells. This model is a derivation of the
complete model by constraining the decay rate of long-lived
plasma cells to 0. Figure 1 displays the observation/prediction plot
(log10 scale) for the asymptotic model (R2 =0.97).
Although care has to be taken using these models based on 10
years of data, long-term individual extrapolations of antibody
kinetics were derived from the individual empirical parameter
estimates for each model (complete, adiabatic and asymptotic) and
the two data sets (Figure 2). In accordance with international
current practice, the positivity threshold was fixed to 20 mIU/ml
and subjects with antibody levels below this threshold for the
ELISA test were considered seronegative. Immunity was consid-
ered as lost when a subject passed from seropositive to
seronegative status [24,34]. A focus around the positivity threshold
(20 mIU/ml, thick black line) was plotted for each model and
dataset to monitor the population serological response according
to time post-boosting. For the first dataset, including only one
point in the first year after vaccination (1 month), the asymptotic,
complete and power-law models gave similar results with a life-long
immunity for all vaccinated patients. Conversely, for the adiabatic
PCDK model a proportion of the population loses humoral
immunity, with the first seronegative patient occuring 20 years
after vaccination. However, the proportion of seronegative patients
100 years after vaccination did not exceed 15% (figure 3), showing a
good long-term efficacy of the vaccine. The mean time to immunity
waning was 216 years (95%confidence interval [143.0, 848.6],
table 3). The results for the second data set differ according to the
model assumptions. Although the asymptotic model gave similar
results as for the first dataset predicting lifelong immunity due to the
supposed asymptot, results with the complete and adiabatic
approach were divergent. The complete model was found closer
to the adiabatic due to the existence of an additional sample time in
the early phase of the kinetics (6 months). Although the power-law
models predicted lifelong immunity for both vaccines, the estimate
of the decay rate of long lived plasma-cells was found to be higher
for the second dataset, confirming that the ‘‘plateau’’ assumption in
the asymptotic model provides crude approximations of the actual
long-term kinetics. Adiabatic model predictions showed that the
total population lost immunity within 100 years after vaccination.
Moreover, the mean time to lose immunity was evaluated to be 43
years (95% confidence interval [34.8, 52.0]; Table 3).
Discussion
A mathematical model, based on the ‘‘imprinted plasma cell lifespan
model’’ proposed by Amanna and Slifka, was developed to study the
Table 2. Parameter estimates using power-law model (95% confidence intervals determined using bootstrap percentile intervals).
Population parameter estimates (CI)
Havrix
TM 1440 dataset Havrix
TM 720 dataset
Parameters
Conventional
power-law
Asymptotic
power-law Full power-law
Conventional
power-law
Asymptotic
power-law Full power-law
k 4.13 (4.04, 4.18) 5.87 (5.67, 6.12) 6.21 (5.65, 6.97) 4.00 (3.89, 4.10) 5.29 (4.48, 5.74) 6.37 (6.12, 6.55)
a 0.63 (0.59, 0.67) 2.26 (2.07, 2.50) 2.79 (2.09, 3.40) 0.60 (0.54, 0.66) 2.01 (0.93,2.48) 3.67 (3.28, 3.88)
p - 8.1e
24 (4.3e
24, 1.2e
23) 0.0008 (1.8e
24, 1.4e
23) - 3.2e
23 (1.3e
23, 5.1e
23) 1.7e-
3 (9.7e
24, 2.8e
23)
b - - 0.08 (1.8e
23, 0.16) - - 0.37 (0.29, 0.43)
AIC 2572.83 21226.77 21255.01 2128.36 2204.26 2297.35
doi:10.1371/journal.pcbi.1002418.t002
Figure 1. Observations Vs. model predictions (left) and residuals Vs Time (right) plots using individual parameters (Havrix
TM 720
dataset, Asymptotic model, log10 scale).
doi:10.1371/journal.pcbi.1002418.g001
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inactivated HAV vaccines [2]. Previous studies showed that anti-
HAV antibodies can persist for at least 25 years and that a two-
phase decay of antibody levels occurs according to the time since
vaccination [35,36]. However, the models used for the estimations
were solely based on the antibody dynamics and did not handle
the underlying immunological mechanisms. Plasma-cells are the
main antibody-secreting cells and it is currently recognized that
some of these cells can survive for extended periods when located
in survival niches, especially in the bone marrow [12,13,14]. The
model used in our study assumed that the antibody kinetics are
determined by three time-scales: the antibody, the short-lived
plasma cell and long-lived plasma cell lifespans (complete model).
Two other approaches were derived from the complete model:
(i) assuming a constant long-lived plasma cell population
(asymptotic model) close to the model of Fraser et al. [20].
(ii) ignoring the antibody lifespan (assumed to be short compared
with plasma-cell lifespans (plasma cell driven kinetic model)).
The complete model, which should be the best representation of
the actual process including three time-scales (antibody, long- and
short-lived cell life-spans), did not allow for accurate estimates,
especially concerning the decay rate of long-lived plasma cells
(RSE.200%). The asymptotic model permits to estimate the
antibody decay rate corresponding to the shortest time scale
(around 1 month) [3]. However the hypothesis of the asymptotic
model, assuming a constant antibody production by long-lived
plasma cells residing in niches in the bone marrow and considered
as surviving in the host for life, generates a cost on long-term
predictions of the antibody decay which cannot be studied using
this approach. The third approach, called ‘‘plasma cell driven
kinetic’’, considers the antibody kinetics to immediately reflect the
underlying kinetics of plasma cell populations. Thus, ignoring the
antibody decay, which cannot be distinguished from plasma-cells,
allows for fitting the long-term kinetics. However, the interpreta-
tion of the parameters is not straightforward, especially when
detailed data are available in the initial phase of the kinetics, which
corresponds to the antibody decay (table 2). Although our model
selection criterion (AIC) tends to select the asymptotic model, all
three models have their own interest depending on the research
question:
Figure 2. Individual prediction plots with a focus around the positivity threshold (20 mIU/ml, black line). (a,c,b) Havrix
TM 1440 dataset,
(d,e,f) Havrix
TM 720 dataset; (a,d) complete model, (b,e) plasma-cell driven kinetics model, (c,f) asymptotic model.
doi:10.1371/journal.pcbi.1002418.g002
Figure 3. Predicted proportion of seropositive patients accord-
ing to time post vaccination from the plasma-cell driven
kinetics model (full blue line: Havrix
TM 1440 dataset , dashed
green line: Havrix
TM 720 dataset).
doi:10.1371/journal.pcbi.1002418.g003
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and particularly the duration of antibody lifespan.
2) Plasma cell driven kinetic model: Study of long-term
behavior, permitting to estimate the mean time to waned
immunity.
3) Complete model: Global approach that could allow dealing
with the two previous research questions. However, this
approach would need additional data, especially in the initial
phase of the antibody decay after vaccination, which would
permit to identify the transition between the adiabatic and
the asymptotic hypotheses.
Combining the results obtained with each of these models, the
average antibody lifespan was estimated to be around one month
that is consistent with the literature whereas the average plasma
cell lifespans varied from 3 to 7 months for short-lived plasma-
cells, and over 60 years for long-lived plasma cell.
Power-law models present a relevant alternative to the
modelling framework based on plasma cells imprinted lifespan,
both from a methodological and from a biological point of view. In
absence of emperical evidence for ‘‘heterogeneity in the decay rate
of B-cells’’ given the data at our disposal, exponential decays were
assumed for short-lived and long-lived plasma-cells. The main
results of our study rely on the fact that three time-scales were
biologically relevant to explain the antibody decay: the antibody,
the short-lived and long-lived plasma cell lifespans. The power-law
models as described in Fraser et al. [20] included at most two time-
scales, which could explain the differences observed in the fits.
This conclusion is supported by the results obtained with the
‘‘Plasma-Cell Driven Kinetics’’ (PCDK) model, which accounted
for two time-scales and for which the AIC values were close to the
one obtained with the full power-law model (also accounting for
two time scales). Thus, whenever relevant data would be available,
the coupling of the two approaches offers an appealing perspective
for future immunological research.
Using individual parameter estimates, the mean time to
immunity waning was estimated to be 43 years for the individuals
vaccinated with Havrix
TM 720 vaccine. Similar results were
previously obtained by Van Herck et al. [16] who estimated the
individual slow decay rate of antibodies (between months 76 and
128 post boosting) and estimated the mean number of years before
an individual reached the seroconversion level (20mIU/ml) to 45
years. With the same methodology, less than 15% of individuals
vaccinated with the latest vaccine formulation (Havrix
TM 1440)
were estimated to lose their immunity 100 years after boosting,
showing possible life-long vaccine-induced immunity. Although
these results are based on long-term extrapolation and could be
influenced by immunosenescence and other distortions of
immunity, they elucidate in a simple way the observed differences
between the two vaccines.
Accounting for correlations between random effects was not
found to impact the accuracy of parameter estimates obtained with
the PCDK model (data not shown). Computational problems, due
to convergence failure, avoided the inclusion of such correlations
when analyzing the data with the asymptotic and complete
models. However, based on the results obtained with the PCDK
model, the main conclusions of this study are deemed to be robust
to this specific misspecification of the random effects distribution.
The effect of such misspecification would require further research
which is beyond the scope of the present study.
These results have a number of direct implications:
N In immunology, it offers a quantitative assessment of the time
scales over which plasma cells and antibodies live and interact.
This insight may provide a basis for further quantitative
research on the immunology, with direct consequences for
understanding the epidemiology of infectious diseases.
N In vaccinology, it offers an opportunity for clinical trial
researchers to collect relevant information early on, in order to
make long term predictions on immunity conferred by
vaccines. We showed in particular that antibody levels
measured within a year after a booster dose provide highly
relevant information for long term predictions of protective
immunity over time.
N In health policy, it offers more than a purely intuitive basis to
make recommendations on booster vaccinations. Our models
for hepatitis A suggest that this would not be required at least
within a 40 year time span after the booster vaccine dose.
A further improvement of our mathematical model could
include the explicit interaction between humoral and cellular
immunity. This would involve nonlinear coupling terms. The
validation of such theoretical generalisations would require much
more refined data not only about antibodies but also about B-cell
and T-cell subpopulations.
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Table 3. Long-term prediction of HAV antibody dynamics obtained with complete and plasma cell driven kinetics (PCDK) models
(95% confidence intervals determined using bootstrap percentile intervals).
Havrix
TM 1440 dataset Havrix
TM 720 dataset
Complete Model PCDK Model Complete Model PCDK Model
Mean Time to immunity waning (years) 1.7e
5 (4.7e
4, 6.7e
6) 216.1 (143.0, 848.6) 237.1 (188.5, 1.7e
3) 43 (34.8, 52.0)
Time below 95% of immune patients (years) 7.6e
4 (1.7e
4, 3.4e
5) 63 (31.6, 576.9) 147.1 (111.2, 1.1e
3) 23.4 (17.7, 25.3)
Time below 90% of immune patients (years) 1.0e
5 (2.8e
4, 4.3e
5) 77.4 (52.6, 681.4) 169.4 (126.6, 1.2e
3) 24.4 (22.2, 29.3)
doi:10.1371/journal.pcbi.1002418.t003
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